Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuliano Rizzardini

Showing results (1-10 of 248) with videos related to

Pageof 25
Sort By:
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|December 1, 2006
Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: a reviewGiuliano Rizzardini, Amedeo Capetti
Expert Opinion on Pharmacotherapy|January 25, 2019
Choosing appropriate pharmacotherapy for drug-resistant HIVAmedeo Capetti, Giuliano Rizzardini
Expert Opinion on Pharmacotherapy|May 14, 2014
Cobicistat : a new opportunity in the treatment of HIV disease?Amedeo Capetti, Giuliano Rizzardini
Expert Opinion on Pharmacotherapy|July 27, 2011
Abacavir and lamivudine for the treatment of human immunodeficiency virusGiuliano Rizzardini, Patrizia Zucchi
AIDS (London, England)|May 11, 2018
Seroconversion on preexposure prophylaxisGiuliano Rizzardini, Dean L Winslow
AIDS (London, England)|March 9, 2017
Intolerance of dolutegravir-containing combination antiretroviral therapy: not just a pharmacokinetic drug interactionDario Cattaneo, Giuliano Rizzardini, Cristina Gervasoni
Expert Opinion on Drug Metabolism & Toxicology|February 2, 2019
Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatmentDario Cattaneo, Amedeo Capetti, Giuliano Rizzardini
AIDS (London, England)|December 20, 2015
Managing hepatitis C virus-HIV liver transplant recipients with the new direct-acting antivirals: are we glimpsing a brilliant future behind our shoulders?Stefano Fagiuoli, Massimo Puoti, Giuliano Rizzardini
Le Infezioni in Medicina|September 25, 2018
What is new in infectious diseases: Nipah virus, MERS-CoV and the Blueprint List of the World Health OrganizationGiuliano Rizzardini, Tommaso Saporito, Alessandro Visconti
AIDS (London, England)|October 26, 2013
The management of antiretroviral treatments in Europe: the Italian experienceGiuliano Rizzardini, Umberto Restelli, Davide Croce
Pageof 25

Showing results (1-10 of 248) with videos related to

Sort By:
Pageof 25
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|December 1, 2006
Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: a reviewGiuliano Rizzardini, Amedeo Capetti
Expert Opinion on Pharmacotherapy|January 25, 2019
Choosing appropriate pharmacotherapy for drug-resistant HIVAmedeo Capetti, Giuliano Rizzardini
Expert Opinion on Pharmacotherapy|May 14, 2014
Cobicistat : a new opportunity in the treatment of HIV disease?Amedeo Capetti, Giuliano Rizzardini
Expert Opinion on Pharmacotherapy|July 27, 2011
Abacavir and lamivudine for the treatment of human immunodeficiency virusGiuliano Rizzardini, Patrizia Zucchi
AIDS (London, England)|May 11, 2018
Seroconversion on preexposure prophylaxisGiuliano Rizzardini, Dean L Winslow
AIDS (London, England)|March 9, 2017
Intolerance of dolutegravir-containing combination antiretroviral therapy: not just a pharmacokinetic drug interactionDario Cattaneo, Giuliano Rizzardini, Cristina Gervasoni
Expert Opinion on Drug Metabolism & Toxicology|February 2, 2019
Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatmentDario Cattaneo, Amedeo Capetti, Giuliano Rizzardini
AIDS (London, England)|December 20, 2015
Managing hepatitis C virus-HIV liver transplant recipients with the new direct-acting antivirals: are we glimpsing a brilliant future behind our shoulders?Stefano Fagiuoli, Massimo Puoti, Giuliano Rizzardini
Le Infezioni in Medicina|September 25, 2018
What is new in infectious diseases: Nipah virus, MERS-CoV and the Blueprint List of the World Health OrganizationGiuliano Rizzardini, Tommaso Saporito, Alessandro Visconti
AIDS (London, England)|October 26, 2013
The management of antiretroviral treatments in Europe: the Italian experienceGiuliano Rizzardini, Umberto Restelli, Davide Croce
Pageof 25